Weve talked to you about 1.Medicines Waste 2.Over the counter - PowerPoint PPT Presentation

Jul 25, 2020 •567 likes •662 views

Weve talked to you about 1.Medicines Waste 2.Over the counter prescribing 3.and now 1 Medicines waste Weve lots of photos like these 3 Medicines Waste Results All practices have stopped third party ordering Empowering

We’ve talked to you about 1.Medicines Waste 2.Over the counter prescribing 3.and now 1
Medicines waste
We’ve lots of photos like these 3
Medicines Waste Results • All practices have stopped third party ordering • Empowering patients to take back control of their medication • Savings – £1,555,526 16/17 – £401,372 15/16 – Total = £1,956,898
Over the counter medication Over 10,000 • NHS England consultation responses nearly 50% from Rotherham residents 5
Over the counter medication 37 indications 17/18 Rotherham spent 2 million on Simple painkillers these products Vitamins 80% of patients said Skin creams that they would be happy to buy Laxatives Cough & cold remedies 6
• Our next conversation • This is our biggest challenge to date 7
Antidepressants 8
Antidepressants • What % of the population of England takes an antidepressant? • How long do they take to work • When would you think that you would need an antidepressant? • How easy is it to stop taking an antidepressant ? 9

Recommend

Psychotropic Use in Adolescents and Young Adults Sheila Botts, PharmD, BCPP, FCCP Chief,

Weighty Issues with Psychotropic Use in Adolescents and Young Adults Sheila Botts, PharmD, BCPP, FCCP Chief, Clinical Pharmacy Research & Academic Affairs Kristen N. Gardner, PharmD Clinical Pharmacy Specialist Behavioral Health Kaiser

689 views • 45 slides

BEREAVEMENT AND SUICIDE Using administrative data to understand mental health in Northern

MENTAL HEALTH, BEREAVEMENT AND SUICIDE Using administrative data to understand mental health in Northern Ireland: Results from two exemplar projects Dr Aideen Maguire 1 , Dr Mark McCann 2 , Dr John Moriarty 3 and Dr Dermot OReilly 1 1 UKCRC

533 views • 25 slides

Depression Jennifer L. Payne, M.D. Director , Womens Mood Disorders Center Johns Hopkins

Prevention of Postpartum Depression Jennifer L. Payne, M.D. Director , Womens Mood Disorders Center Johns Hopkins School of Medicine Postpartum Depression: Who is at Risk? 10-15% of women in general population 25-50% of women with a

653 views • 23 slides

Treating Patients with Depression Using Coordinated Medication Management November 13, 2018

Treating Patients with Depression Using Coordinated Medication Management November 13, 2018 Good Afternoon! Elisabeth Hager, MD, MMM Chief Medical Officer Southeast/Central Region Learning objectives 1) Improve the accuracy of diagnosing

748 views • 59 slides

Fear of Cancer Recurrence: Strategies for Adaptive Coping Shelley A. Johns , PsyD, HSPP, ABPP

Fear of Cancer Recurrence: Strategies for Adaptive Coping Shelley A. Johns , PsyD, HSPP, ABPP Board Certified Clinical Health Psychologist Assistant Professor, IU School of Medicine Research Scientist, Regenstrief Institute Affiliate Faculty,

784 views • 17 slides

Antidepressant Response MarkerRevolutionizing Depression Treatment Hook: Imagine falling into a

Anish Dave 1/24/11 Antidepressant Response MarkerRevolutionizing Depression Treatment Hook: Imagine falling into a ditch. Its dark and lonely. All of a sudden the ditch crumbles on top of you. As much as you keep trying to climb out of this

229 views • 3 slides

How Effective Are the Rapid-Acting Anti-Depressants? A RAAD-ical Argument for Efficacy Mark G.

How Effective Are the Rapid-Acting Anti-Depressants? A RAAD-ical Argument for Efficacy Mark G. A. Opler, PhD, MPH Chief Research Officer MedAvante-ProPhase Inc. Dangerous Street Drugs vs. Miracle Cures Voice of the Patient for example,

341 views • 14 slides

Rapid-Acting Anti-Depressants? The search for the holy grail Torsten M. Madsen MD, Ph.D Chief

Rapid-Acting Anti-Depressants? The search for the holy grail Torsten M. Madsen MD, Ph.D Chief Medical Officer Aptinyx Inc. RAAD seminar Disclosures: Full time employee at Aptinyx (previous employee at Naurex, Lundbeck) Holds

418 views • 20 slides

Th The neurog ogenic a c antidepressant c com ompou ound, N NSI SI-189 189, shows pot

Th The neurog ogenic a c antidepressant c com ompou ound, N NSI SI-189 189, shows pot otential a as a broa oad n neurot otrop ophic a c agent Karl Johe, Ph.D. Chief Scientific Officer NEURALSTEM, INC. Safe Harbor &

600 views • 31 slides

Astrodepressants Antidepressants Targeting Astrocytes Dr. Jimmy Stehberg June, 2019 Aleph

Astrodepressants Antidepressants Targeting Astrocytes Dr. Jimmy Stehberg June, 2019 Aleph Pharmaceuticals PROBLEMS WITH CURRENT ANTIDEPRESSANTS 50% of people with depression do not respond to current antidepressants. Current

379 views • 11 slides

GInAS Herman Diederik and Ciska G. Matai, CBG-MEB Thomas Balzer, BfArM Vikesh Srivastava, Health

Implementation of ISO/IDMP 11238 Substance Standard and Movement towards a Global Ingredient Archival System GInAS Herman Diederik and Ciska G. Matai, CBG-MEB Thomas Balzer, BfArM Vikesh Srivastava, Health Canada Larry Callahan, Frank

1.03k views • 65 slides

13 15 February 2019 Organized by Department of Chemistry, SRM IST, Kattankulathur

31 3 rd INTERNATIONAL CONFERENCE ON RECENTADVANCES IN MATERIAL CHEMISTRY (ICRAMC 2019) 13 15 February 2019 Organized by Department of Chemistry, SRM IST, Kattankulathur 603203,India In Association with Alternative Energies and Atomic

255 views • 9 slides

LATUDA Clinical Development Update LATUDA Meeting (Tokyo) January 2011 Antony Loebel, MD

LATUDA Clinical Development Update LATUDA Meeting (Tokyo) January 2011 Antony Loebel, MD Executive Vice President Clinical Research and Medical Affairs Sunovion Pharmaceuticals Inc. Agenda LATUDA Label Overview Approval timeline

594 views • 36 slides

Team : Dr. Erick Turner, Dr. Ben Goldacre and the OpenTrials team at Open Knowledge

Team : Dr. Erick Turner, Dr. Ben Goldacre and the OpenTrials team at Open Knowledge International OpenTrials aims to locate, match and share all publicly accessible data and documents, on all trials conducted, on all medicines and other

499 views • 5 slides

PAX, magnets and mushrooms R. Hamish McAllister-Williams, Professor of Affective Disorders

PAX, magnets and mushrooms R. Hamish McAllister-Williams, Professor of Affective Disorders Academic Lead, NCMD NCMD Aims To provide more hope to more people with mood disorders through an improvement of clinical care for patients brought

288 views • 28 slides

Erica Ellis Bartling PROGRAM COORDINATOR 215 South Walker Street (304) 913-4956 | Office

Erica Ellis Bartling PROGRAM COORDINATOR 215 South Walker Street (304) 913-4956 | Office Princeton, WV 24740 (918) 273-8597 | Cell RENEW renew r n(y)o o/ to restore; to re-establish; to resume after an interruption WHAT

537 views • 49 slides

Precision Medicine in Mental Health Care Study PI: David Oslin, MD VETERANS HEALTH

Precision Medicine in Mental Health Care Study PI: David Oslin, MD VETERANS HEALTH ADMINISTRATION 11/21/17 Background: Public Health Significance Depression is one of the worlds great public health problems At least 1 in 7 Veterans

511 views • 18 slides

Dr Caleb Armstrong Youth and Adult Psychiatrist Treatment Medico-legal and Forensic Reports

Dr Caleb Armstrong Youth and Adult Psychiatrist Treatment Medico-legal and Forensic Reports Auckland 14:30 - 15:00 Ketamine for Depression in a GP Setting Ketamine for Treatment Resistant Depression: a GP model of care? GPCME 2018

1.23k views • 14 slides

Advanced Interactive Case-based Workshop on Pharmacology on Depression and Dementia

Advanced Interactive Case-based Workshop on Pharmacology on Depression and Dementia ___________________________________________________________________________ Benoit H. Mulsant, MD, MS, DFAPA Professor and Chair Department of Psychiatry

681 views • 5 slides

BNC210 Phase 2 PTSD Clinical Trial Results Presentation BNO (Australia: ASX) BNOEF (USA: OTCQX)

BNC210 Phase 2 PTSD Clinical Trial Results Presentation BNO (Australia: ASX) BNOEF (USA: OTCQX) 2 October 2018 Central Nervous System (CNS) Safe Harbor Statement Factors Affecting Future Performance This presentation contains

740 views • 24 slides

Well-Being Therapy by Giovanni A. Fava, M.D. In the nineties, as other investigators, I was

Well-Being Therapy by Giovanni A. Fava, M.D. In the nineties, as other investigators, I was particularly concerned about the high risk of relapse in depression and its link with residual symptomatology (1). It was not easy to make the patients

233 views • 12 slides

Rules Engine National Quality Measures Ross Merritt, MPH Analytic Consultant August 2010

Rules Engine National Quality Measures Ross Merritt, MPH Analytic Consultant August 2010 AGENDA Brief definitions Structure Quality measures in the DAI How the measures are different than HEDIS Gaps in Care measures in

433 views • 18 slides

The Place for Treatments of Associated Neuropsychiatric and Other Symptoms in Alzheimers

The Place for Treatments of Associated Neuropsychiatric and Other Symptoms in Alzheimers Disease and Other Dementias The Patient and Carers Perspective Mary-Frances Morris, Trustee, Alzheimer Scotland. The Alzheimer Associations

317 views • 19 slides

Approaches to Quality Sleep Culture in LTC Sponsored by the Quality Improvement Organizations

Approaches to Quality Sleep Culture in LTC Sponsored by the Quality Improvement Organizations Comagine Health and Great Plains Quality Innovation Network Approaches to Quality Sleep Culture in LTC Leah Brandis, MPH, RDN Oregon QIO

1.21k views • 55 slides